Methods and compositions for treating diseases, disorders or injury of the cns
AssigneeQuark Pharmaceuticals, Inc.
InventorsElena Feinstein, Igor Spivak, Evgenia Alpert, Ron Lahav
Life of this patent
Estimating the term…
Abstract
The present invention relates to non-invasive methods for treating diseases, disorders and injury to the central nervous system (CNS), and in particular to otic compositions and to methods of use thereof.
Claims27
A method for inhibiting loss or injury of a retinal ganglion cell in a subject, comprising applying to the ear of the subject an otic composition comprising at least one double stranded RNA compound which down regulates expression of a target gene associated with loss of the retinal ganglion cell, in an amount effective to inhibit loss or injury of the retinal ganglion cell in the subject.
4-5. (canceled)
9-15. (canceled)
A method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of an ocular disease associated with death of a retinal ganglion cell in a subject, comprising applying to the ear of the subject an otic composition comprising at least one double stranded RNA compound which down regulates expression of a target gene associated with the ocular disease, in an amount effective to provide ocular neuroprotection or prevent or treat the disease or alleviate the effects of the disease in the subject.
(canceled)
19-26. (canceled)
An otic composition for treatment of an ocular disease associated with damage to or loss of a retinal ganglion cell in a subject or with pathological abnormalities or changes in the tissues of the visual system in a subject or with a disease, a disorder or an injury of the CNS, comprising:
- (a) a therapeutically effective amount of at least one double stranded RNA compound which down regulates expression of a target gene associated with the ocular disease, and (b) a pharmaceutically acceptable excipient or carrier or mixture thereof.
29-31. (canceled)
33-37. (canceled)
A kit comprising:
- (a) a therapeutic oligonucleotide that targets a gene associated with an ocular disease or a disease, disorder or injury of the CNS;
- and (b) instructions for using the oligonucleotide to treat the disease, disorder or injury.
39-40. (canceled)
(canceled)
A method of attenuating expression of a target mRNA in a subject suffering from a disease, a disorder or an injury of the CNS associated with expression of the target mRNA, which comprises applying to the ear of the subject an otic composition comprising at least one oligonucleotide compound which down regulates expression of the target mRNA and a pharmaceutically acceptable excipient or mixtures thereof, thereby attenuating expression of the target mRNA in the CNS of the subject.
A method of providing neuroprotection to the CNS of a subject or treating a disease, a disorder or an injury of the CNS in a subject, comprising topically applying to the canal of the subject's ear an otic composition comprising at least one oligonucleotide which down regulates expression of a target gene associated with the disease disorder or injury, and a pharmaceutically acceptable excipient or mixtures thereof, thereby providing neuroprotection or treating the subject.
45-62. (canceled)
65-78. (canceled)
Dependencies are inferred from the claim text.